Daiichi Sankyo

AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval
Fierce Biotech
Fri, 12/6/24 - 09:51 am
AstraZeneca
Daiichi Sankyo
Dato-DXd
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Fierce Pharma
Tue, 11/19/24 - 07:14 pm
AstraZeneca
Daiichi Sankyo
Enhertu
UK
NICE
AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again
Fierce Biotech
Tue, 11/12/24 - 08:44 pm
AstraZeneca
Daiichi Sankyo
lung cancer
FDA
Dato-DXd
Enhertu
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Pharmaphorum
Fri, 11/8/24 - 11:37 am
Daiichi Sankyo
Alteogen
Enhertu
cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
FDA
Bridge Bio
acoramidis
AstraZeneca
Daiichi Sankyo
Dato-DXd
Vertex Pharmaceuticals
Vanza Triple
PTC Therapeutics
Upstaza
Bristol Myers Squibb
Opdivo
AstraZeneca's experimental drug disappoints in breast cancer survival trial
Reuters
Mon, 09/23/24 - 11:29 am
AstraZeneca
Daiichi Sankyo
clinical trials
breast cancer
Dato-DXd
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Medical Marketing and Media
Sun, 09/22/24 - 09:46 pm
Daiichi Sankyo
AstraZeneca
breast cancer
metastatic breast cancer
Enhertu
DTC ads
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Fierce Pharma
Thu, 09/19/24 - 11:06 am
artificial intelligence
Bayer
Daiichi Sankyo
Argenx
ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases
Clinical Trials Arena
Tue, 09/17/24 - 11:20 am
ESMO
breast cancer
Daiichi Sankyo
Enhertu
metastatic breast cancer
clinical trials
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Reuters
Tue, 09/17/24 - 09:51 am
Daiichi Sankyo
Merck
patritumab deruxtecan
clinical trials
non-small cell lung cancer
AstraZeneca steps out from Daiichi's shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Fierce Biotech
Sun, 09/15/24 - 06:25 pm
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data
Fierce Biotech
Mon, 09/9/24 - 11:30 am
Merck
Daiichi Sankyo
I-DXd
small cell lung cancer
clinical trials
EU starts review of Enhertu in HER2-ultra-low breast cancer
Pharmaphorum
Mon, 08/19/24 - 09:56 am
EMA
Europe
AstraZeneca
Daiichi Sankyo
breast cancer
Enhertu
Merck advances lung cancer attack, pocketing $170M from Daiichi and plotting ADC-trispecific combo
Fierce Biotech
Tue, 08/6/24 - 11:20 am
Merck
Harpoon Therapeutics
Daiichi Sankyo
small cell lung cancer
Daiichi Sankyo and MSD announce first subject dosing in lung cancer trial
Clinical Trials Arena
Fri, 08/2/24 - 11:50 am
Daiichi Sankyo
Merck
clinical trials
I-DXd
small cell lung cancer
After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds
Fierce Pharma
Mon, 07/29/24 - 10:51 am
AstraZeneca
Daiichi Sankyo
Enhertu
NICE
UK
HER2-low breast cancer
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
BioSpace
Mon, 07/1/24 - 11:14 am
Daiichi Sankyo
Seagen
patents
Enhertu
FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
Reuters
Thu, 06/27/24 - 11:18 am
Merck
Daiichi Sankyo
cancer
FDA
patritumab deruxtecan
antibody-drug conjugate
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer
Fierce Pharma
Sun, 06/2/24 - 02:46 pm
ASCO 2024
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer

Pages